ImpediMed

ImpediMed Total Assets

The Total Assets of ImpediMed (IPD.AX) as of Oct 9, 2026 is 34.66 M AUD. In the previous year, Total Assets was 41.66 M AUD — a change of -16.80% (lower).

Total Assets

34.66 MAUD

YoY

-16.80%

Last updated:

Total Assets of ImpediMed is 2026 34.66 M AUD. Total Assets of ImpediMed was 2025 41.66 M AUD. It decreases by -16.80% lower compared to the previous year.

The ImpediMed Total Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Total Assets
Date
Total Assets
Jan 1, 2019
22.58 M AUD
Jan 1, 2020
33.06 M AUD
Jan 1, 2021
34.21 M AUD
Jan 1, 2022
58.70 M AUD
Jan 1, 2023
68.74 M AUD
Jan 1, 2024
46.99 M AUD
Jan 1, 2025
41.66 M AUD
Jan 1, 2026
34.66 M AUD
The ImpediMed Total Assets history
YEARTotal AssetsYoY
34.66 MAUD-16.80%
41.66 MAUD-11.34%
46.99 MAUD-31.64%
68.74 MAUD+17.10%
58.70 MAUD+71.61%
34.21 MAUD+3.45%
33.06 MAUD+46.42%
22.58 MAUD-45.68%
41.57 MAUD-35.39%
64.34 MAUD-28.96%
90.57 MAUD+138.86%
37.92 MAUD+153.49%
14.96 MAUD—
Access this data via the Eulerpool API

ImpediMed Stock analysis

What does ImpediMed do? ImpediMed Ltd is an Australian company specializing in medical devices and technologies. They were founded in 1999 and have their headquarters in Brisbane, Australia. The company is a leading provider of bioimpedance measurement devices for the diagnosis, monitoring, and treatment of lymphatic, cardiac, and other medical conditions. They have a wide range of products used in various medical fields, including oncology, lymphology, and cardiology. Their main business model is based on the development and marketing of their bioimpedance measurement devices. They also provide training and support for medical personnel to optimize the use of their devices. ImpediMed specializes in the diagnosis and treatment of lymphedema in the oncology sector, particularly using their highly precise L-Dex® device. They also analyze body composition in the cardiology sector to determine the risk of heart diseases and develop personalized treatment approaches. In recent years, ImpediMed has expanded into the European market, particularly in lymphedema diagnosis and treatment. Overall, ImpediMed Ltd is an innovative company that focuses on medical devices and technologies for the diagnosis and monitoring of cardiac and lymphatic diseases. They provide important diagnostic capabilities to medical professionals and continue to focus on growth and expansion. ImpediMed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ImpediMed stock

Total Assets of ImpediMed is 34.66 M AUD in 2026.

Total Assets of ImpediMed changed from 41.66 M AUD to 34.66 M AUD, representing a -16.80% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets ImpediMed since 2006 – with annual values, charts, and detailed analysis.

Total assets represent everything a company owns, including cash, inventory, property, and intangible assets. It is a key measure of a company's size and resource base.

Total Assets's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Total Assets's ImpediMed historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — ImpediMed

All Key Metrics — ImpediMed